Company / Return on Equity (ROE)
Avalo Therapeutics, Inc. Return on Equity (ROE) History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-94.2%
FY2025
5-year range
-431.9% / -26.4%
FY2021-FY2025
Trend
-256.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Avalo Therapeutics, Inc. reports negative total equity of -94.2% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-94.2% in FY2025 with a 5-year CAGR of +164.3%.
Improved from -431.9% to -94.2% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -
- 5-Year Change
- +164.3pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2025, return on equity (roe) decreased 256.8% year-over-year.
- Peak return on equity (roe) was recorded in FY2017.
- Lowest return on equity (roe) in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.59 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -94.2% | -256.8% |
| FY2024 | -26.4% | +93.9% |
| FY2023 | -431.9% | - |
| FY2022 | - | - |
| FY2021 | -365.6% | -41.4% |
| FY2020 | -258.5% | -237.7% |
| FY2019 | -76.5% | +60.0% |
| FY2018 | -191.6% | -549.6% |
| FY2017 | 42.6% | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 21, 2026